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Pre-transmembraneembranotropic regions of the HCV E1 envelope glycoprotein, a class II membrane
fusion protein, permitted us to identify different sequences which might be implicated in viral membrane
fusion, membrane interaction and/or protein–protein binding. HCV E1 glycoprotein presents a membrano-
active region immediately adjacent to the transmembrane segment, which could be involved in membrane
destabilization similarly to the pre-transmembrane domains of class I fusion proteins. Consequently, we have
carried out a study of the binding and interaction with the lipid bilayer of a peptide corresponding to
segment 309–340, peptide E1PTM, as well as the structural changes which take place in both the peptide and
the phospholipid molecules induced by the binding of the peptide to the membrane. Here we demonstrate
that peptide E1PTM strongly partitions into phospholipid membranes, interacts with negatively-charged
phospholipids and locates in a shallow position in the membrane. These data support its role in HCV-
mediated membrane fusion and suggest that the mechanism of membrane fusion elicited by class I and II
fusion proteins might be similar.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionHepatitis C virus (HCV) has an important impact on public health
since it is the leading cause of acute and chronic liver disease, such as
chronic hepatitis, cirrhosis, and hepatocellular carcinoma [1–3]. The
HCV genome is widely heterogeneous and replication errors cause a
high rate of mutations [4]. There exists no vaccine to prevent HCV
infection and current therapeutic agents have limited efﬁcacy against
the virus [5]. The variability of the HCV proteins gives the virus the
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l rights reserved.hampers the development of an efﬁcient vaccine. The HCV genome
encodes a polyprotein precursor that is cleaved by host and viral
proteases to yield ten mature structural and non-structural proteins
[6]. HCV entry into the cell is achieved by the fusion of viral and cellular
membranes, and morphogenesis and budding has been suggested to
take place in the endoplasmic reticulum, ER [7]. Therefore, the viral
region implicated in fusion to and/or budding from the cells must
interact with the membrane and should be a conserved sequence.
Thus, ﬁnding inhibitors of protein–membrane and protein–protein
interactions involved in virus fusion and/or budding could be an
alternative and valuable strategy against HCV infection since they
could be potential therapeutic agents.
The fusion of viral and cellular membranes, the critical early
events in viral infection, are mediated by class I, II and III envelope
fusion glycoproteins located on the outer surface of the viral mem-
branes [8–12]. Whereas class I membrane fusion proteins possess
a fusion peptide at or near the amino terminus, a pair of extended
α-helices and, generally, a cluster of aromatic amino acids proximal
to a hydrophobic transmembrane domain, class II fusion proteins
possess an internal fusion peptide located at a distal location from
the transmembrane anchor, as well as different domains comprised
mostly of antiparallel β-sheets [9,13]. Class III fusion proteins have
features in common to both class I and II proteins [14]. Their three
dimensional structure is different but their function is identical, so
that they must share structural and functional characteristics in
speciﬁc domains which interact with and disrupt biological mem-
branes [13,15,16]. HCV E1 and E2 envelope glycoproteins are es-
sential for receptor binding, host cell entry and membrane fusion,
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not known [8,17–20]. E1 and E2 are type I transmembrane (TM)
glycoproteins, with an N-terminal ectodomain and a short C-terminal
TM domain and assemble as non-covalent heterodimers. Their TM do-
mains play amajor role in the E1/E2 heterodimer formation, membrane
anchoring, and ER retention [21–24]. The HCV envelope glycoproteins
E1 and E2 are included in the class II fusion proteins, and the putative
fusion peptide is localized in an internal sequence linked by antiparallel
β-sheets [8,9]. The HCVmembrane fusion process is pH-dependent, and
lowendosomal pHpromotes the arrangementof E1/E2 to its active form
[25].Manyaspects regarding the function and properties of bothHCV E1
and E2 glycoproteins still remainunresolved; even so, the location of the
fusion peptide is controversial since several data suggest that it could be
located in either E1 or E2. Althoughprevious data have proposed a direct
role of HCV E1 on membrane fusion whereas HCV E2 should mediate
the binding with receptor CD81 as well as be responsible of hetero-
dimerization with E1, recent data suggest that indeed both E1 and E2
glycoproteins participate in the membrane fusion mechanism [17,25–
28]. Several hydrophobic patches have been identiﬁed in both E1 and E2
envelope glycoproteins whichmight be important in the mechanism of
membrane fusion, not only for modulating membrane binding and
interaction, but also for protein–protein interaction [19,27–30].
Studieswith a number of viral fusionproteins have showed that the
region immediately adjacent to themembrane-spanning domainplays
an essential role in the fusogenic activities of these proteins, being a
common characteristic to viral fusion proteins of several virus families
[31–33]. These pre-transmembrane (PTM) domains would function as
promoters of membrane destabilization [34–36]. We have recently
identiﬁed the membrane-active regions of the HCV E1 and E2 gly-
coproteins by observing the effect of E1 and E2 glycoprotein-derived
peptide libraries onmodelmembrane integrity [29]. These results have
permitted us to suggest the possible location of different segments in
these proteins which might be implicated in protein–lipid and
protein–protein interactions. In particular, E1 presents three membra-
notropic segments encompassing approximately residues 265–296,
310–348 and 349–381 (Fig. 1) [16,20,29]. Segment 265–296 has been
suggested to be the putative fusionpeptide,whereas segment 349–381
deﬁnes the E1 TMdomain. The region encompassing residues 310–348
is located immediately adjacent to the TMdomain, presents a localizedFig. 1. Schematic view of the organization of the whole sequence of HCV E1 glycoprotein
transmembrane, PTM, and transmembrane, TM), as well as the corresponding hydrophob
average leakage (L) (for details see Refs. [29,55]). Only positive bilayer-to-water transfer free
studied in this work is shown and highlighted in the ﬁgure with dotted lines.high hydrophobic moment surface area and is capable of destabilizing
model membranes. Although its sequence does not present a high
content of aromatic amino acids asmembrane fusion proteins of class I
have, it could be involved inmembrane destabilization similarly to the
PTM domains of class I fusion proteins.
It is known that the mechanism by which proteins facilitate the
formation of fusion intermediates is a complex process involving several
segments of fusion proteins [11,37]. However, there are still many
questions to be answered regarding theE1 andE2modeof action inHCV
and cell host membrane fusion. Since the PTM region of the HCV E1
envelope glycoprotein might take part in the fusionmechanism like the
PTM regions found in other proteins, we have focused on the possible
functional roles of the E1 PTM-like domain by an in-depth study of a
peptide patterned after this domain, peptide E1PTM. This peptide
encompasses the 309–340 region of HCV E1 and is the combination of
the sequence of peptides 18 (309-YPGHVSGHRMAWDMMMNW-326), 19
(316-HRMAWDMMMNWSPTTALV-333) and 20 (323-MMNWSPTTAL-
VVSQLLRI-340) from the original HCV E1 peptide library [29]. We have
studied the binding and interaction of E1PTM with the lipid bilayer,
as well as the structural changes induced in both the peptide and
phospholipid molecules upon membrane binding. We show that E1PTM
strongly partitions into phospholipid membranes, interacts with
negatively-charged phospholipids and locates in a shallow position in
the membrane. These results would suggest that the PTM domain
of HCV E1 could be involved in the merging of the viral and target
cell membranes working synergistically with other membrane-active
regions of the protein.
2. Materials and methods
2.1. Materials and reagents
The peptide E1PTM corresponding to the sequence 309-
YPGHVSGHRMAWDMMMNWSPTTALVVSQLLRI-340 from HCV strain
1B4J, with N-terminal acetylation and C-terminal amidation, was
obtained from Genemed Synthesis, San Francisco, Calif. The peptide
E1PTMwaspuriﬁed by reverse-phaseHPLC to better than95%purity, and
its composition and molecular mass were conﬁrmed by amino acid
analysis and mass spectroscopy. Since triﬂuoroacetate has a strongshowing the approximate structural and functional regions (fusion peptide, FP, pre-
ic moment (HM), hydrophobicity (H), interfaciality distribution (I), and experimental
-energy values are shown (the darker, the greater). The sequence of the E1PTM peptide
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the characterization of the peptide Amide I band [38], residual
triﬂuoroacetic acid, used both in peptide synthesis and in the high-
performance liquid chromatography mobile phase, was removed by
several lyophilization/solubilisation cycles in 10 mM HCl [39]. Egg L-α-
phosphatidylcholine (EPC), egg L-α-phosphatidic acid (EPA), lyso-α-
phosphatidylcholine (LPC), egg trans-esteriﬁed L-α-phosphatidyletha-
nolamine (TPE), egg sphingomyelin (SM), bovine brain L-α-phosphati-
dylserine (BPS), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC),
1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DMPG), 1,2-
dimyristoyl-sn-glycero-3-[phospho-L-serine] (DMPS), 1,2-dimyristoyl-
sn-glycero-3-phosphate (DMPA), cholesterol (Chol), liver lipid extract,
lissamine rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-phosphoetha-
nolamine (N-RhB-PE), and N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-
dihexadecanoyl-sn-glycero-3-phosphatidylethanolamine (NBD-PE)
were obtained from Avanti Polar Lipids (Alabaster, AL, USA). 5-
Carboxyﬂuorescein, CF, (N95% by HPLC), ﬂuorescein isothiocyanate
labeled dextrans FD10 and FD20, 5-doxyl-stearic acid (5NS), 16-doxyl-
stearic acid (16NS), sodiumdithionite, deuteriumoxide (99.9% by atom),
Triton X-100, sodium dodecyl sulfate (SDS), EDTA, and HEPES were
purchased from Sigma-Aldrich (Madrid, ES, EU). 1,6-Diphenyl-1,3,5-
hexatriene (DPH), 1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-
hexatriene (TMA-DPH), ﬂuorescein-phosphatidylethanolamine (FPE),
and 4-(2-(6-(dioctylamino)-(2-naphthalenyl) (ethenyl)-1-(3-sulfopro-
pyl)-pyridinium inner salt (di-8-ANEPPS)were obtained fromMolecular
Probes (Eugene, OR). All other reagents used were of analytical grade
from Sigma-Aldrich (Madrid, ES, EU). Water was deionized, twice-
distilled and passed through a Milli-Q equipment (Millipore Ibérica,
Madrid, ES, EU) to a resistivity better than 18 MΩ cm.
2.2. Vesicle preparation
Aliquots containing the appropriate amount of lipid in chloro-
form/methanol (2:1, v/v) were placed in a test tube, the solvents
removed by evaporation under a stream of O2-free nitrogen, and
ﬁnally, traces of solvents were eliminated under vacuum in the dark
for more than 3 h. The lipid ﬁlmswere resuspended in an appropriate
buffer and incubated either at 25 °C or 10 °C above the phase
transition temperature (Tm) with intermittent vortexing for 30 min
to hydrate the samples and obtain multilamellar vesicles (MLV). The
samples were frozen and thawed ﬁve times to ensure complete
homogenization and maximization of peptide/lipid contacts with
occasional vortexing. Large unilamellar vesicles (LUV) with a mean
diameter of 0.1 μm for CF leakage and 0.2 μm for dextran leakage,
hemifusion and fusion experiments were prepared from multi-
lamellar vesicles by the extrusion method [40] using polycarbonate
ﬁlters with a pore size of 0.1 and 0.2 μm (Nuclepore Corp., Cambridge,
CA, USA). The phospholipid and peptide concentrations were
measured by methods described previously [41,42].
2.3. Membrane leakage measurement
LUVs with a mean diameter of 0.1 µm were prepared as indicated
above in buffer containing 10mMTRIS, 20mMNaCl, pH 7.4, and either
CF at a concentration of 40 mM or ﬂuorescein-labeled dextran at a
concentration of 100 mg/ml. Non-encapsulated CF or dextran were
separated from the vesicle suspension through a ﬁltration column
containing Sephadex G-75 or Sephadex S500HR Sephacryl, re-
spectively (Pharmacia, Uppsala, SW, EU), elutedwith buffer containing
10 mM TRIS, 100 mM NaCl, and 0.1 mM EDTA, pH 7.4. Membrane
rupture (leakage) of intraliposomal ﬂuorescent probes was carried out
using 5 mM×5 mm quartz cuvettes stabilized at 25 °C under constant
stirring in a ﬁnal volume of 400 µl (100 µM lipid concentration).
Leakage was assayed until no more change in ﬂuorescence was ob-
tained. The ﬂuorescence was measured using a Varian Cary Eclipse
spectroﬂuorimeter. Changes in ﬂuorescence intensity were recordedwith excitation and emission wavelengths set at 492 and 517 nm,
respectively. Excitation and emission slits were set at 5 nm. The
peptide, dissolved in buffer containing 5% triﬂuoroethanol, was added
to attain the suitable peptide/lipid molar ratio. One hundred percent
releasewas achieved by adding Triton X-100 to a ﬁnal concentration of
0.5% (wt/wt). For details see Refs. [43,44].
2.4. Phospholipid-mixing measurement
Peptide-induced vesicle lipid mixing (hemifusion) was measured
by resonance energy transfer [45]. This assay is based on the decrease
in resonance energy transfer between two probes (NBD-PE and N-
RhB-PE) when the lipids of the probe-containing vesicles are allowed
to mix with lipids from vesicles lacking the probes. The concentration
of each of the ﬂuorescent probes within the liposome membrane was
0.6% mol. LUVs with a mean diameter of 0.2 µm were prepared as
described above. Labeled and unlabeled vesicles in a proportion 1:4
were placed in a 5 mm×5 mm ﬂuorescence cuvette at a ﬁnal lipid
concentration of 100 µM in a ﬁnal volume of 400 µl, stabilized at 25 °C
under constant stirring. The ﬂuorescence was measured using a
Varian Cary Eclipse ﬂuorescence spectrometer using 467 nm and
530 nm for excitation and emission, respectively. Excitation and
emission slits were set at 5 nm. Since labeled and unlabeled vesicles
were mixed in a proportion of 1 to 4, respectively, 100% phospholipid-
mixing was estimated with a liposome preparation in which the
membrane concentration of each probe was 0.12%. Phospholipid-
mixing was quantiﬁed on a percentage basis according to %PM=(Ff−
F0) / (F100−F0) ·100, Ff being the equilibrium value of ﬂuorescence after
peptide addition to a liposome mixture containing liposomes having
0.6% of each probe plus liposomes without any ﬂuorescent probe, F0
the initialﬂuorescence of the vesicles and F100 is theﬂuorescence value
of the liposomes containing 0.12% of each probe. The peptide, dissolved
in buffer containing 5% triﬂuoroethanol, was added to attain the
suitable peptide/lipid molar ratio. Other experimental and measure-
ment conditions were the same as indicated previously [44].
2.5. Inner-monolayer phospholipid-mixing (fusion) measurement
Peptide-induced phospholipid-mixing of the inner monolayer was
measured by amodiﬁcation of the phospholipid-mixingmeasurement
stated above [46]. The concentration of each of the ﬂuorescent probes
within the liposome membrane was 0.6% mol. LUVs with a mean
diameter of 0.2 µm were prepared as described above. LUVs were
treated with sodium dithionite to completely reduce the NBD-labeled
phospholipid located at the outer monolayer of the membrane. The
ﬁnal concentration of sodium dithionite was 100 mM (from a stock
solution of 1 M dithionite in 1 M TRIS, pH 10.0) and incubated for
approximately 1 h on ice in the dark. Sodium dithionite was then
removed by size exclusion chromatography through a Sephadex G-75
ﬁltration column (Pharmacia, Uppsala, Sweden) eluted with buffer
containing 10 mM TRIS, 100 mM NaCl, and 1 mM EDTA, pH 7.4. The
proportion of labeled and unlabeled vesicles, lipid concentration and
other experimental and measurement conditions were the same as
indicated above for the phospholipid-mixing assay.
2.6. Peptide binding to vesicles
The partitioning of the peptide into the phospholipid bilayer was
monitored by the ﬂuorescence enhancement of tryptophan. Fluores-
cence emission spectra were recorded in a SLM Aminco 8000C
spectroﬂuorometer with excitation wavelength of 290 and a 4 nm
spectral bandwidth. Measurements were carried out in 20mMHEPES,
50 mM NaCl, and EDTA 0.1 mM, pH 7.4. Intensity values were
corrected for dilution, and the scatter contribution was derived from
lipid titration of a vesicle blank. The peptide, dissolved in buffer
containing 5% triﬂuoroethanol, was added to attain the suitable
The consensus sequence is shown beneath the alignment.
Table 1
Result of the alignment (CLUSTALW) of residues 309–340 from reference strains
representing the six major genotypes of hepatitis C virus as well as the E1PTM sequence
examined in this work
Fig. 2. (A) Determination of the partition constant, Kp, of E1PTM through the change of the
intrinsic tryptophan ﬂuorescence in the presence of increasing lipid concentrations,
(B) determination of the dissociation constant (Kd) of E1PTM through the change of the
ﬂuorescence signal amplitude of FPE, and (C) Effect of E1PTM on the membrane dipole
potential monitored through the ﬂuorescence ratio (R) of di-8-ANEPPS. The lipid
compositions used were EPC/Chol at a molar ratio of 5:1 (○), BPS/Chol at a molar ratio
of 5:1 (w), EPG/Chol at amolar ratioof 5:1 (☆), EPA/Chol at amolar ratioof 5:1 (△) and lipid
liver extract (□).
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2.7. Steady-state ﬂuorescence anisotropy
MLVs were formed in 100 mM NaCl, 0.05 mM EDTA and 25 mM
HEPES, pH 7.4. Aliquots of TMA-DPH or DPH in N,N′-dimethylforma-
mide (2×10−4 M) were directly added into the lipid dispersion to
obtain a probe/lipid molar ratio of 1/500. Samples were incubated for
15 or 60 min when TMA-DPH or DPH were used, respectively, 10 °C
above the gel-to-liquid crystalline phase transition temperature Tm of
the phospholipid mixture. Afterwards, the peptide dissolved in buffer
containing 5% triﬂuoroethanol, was added to obtain a peptide/lipid
molar ratio of 1:15 and incubated 10 °C above the Tm of each lipid for
1 h, with occasional vortexing. All ﬂuorescence studies were carried
using 5mm×5mmquartz cuvettes in a ﬁnal volume of 400 µl (315 µM
lipid concentration). All the data were corrected for background
intensities and progressive dilution. The steady-state ﬂuorescence
anisotropy, brN, was measured with an automated polarization
accessory using a Varian Cary Eclipse ﬂuorescence spectrometer,
coupled to a Peltier device for automatic temperature change The data
were analyzed as previously described [44].
2.8. Fluorescence quenching of Trp emission by water-soluble and
lipophylic probes
For acrylamide quenching assays, aliquots from a 4M solution of the
water-soluble quencher were added to the solution-containing peptide
in thepresence and absenceof liposomes at apeptide/lipidmolar ratio of
1:100. The results obtained were corrected for dilution and the scatter
contribution was derived from acrylamide titration of a vesicle blank.
The datawere analyzed according to the Stern–Volmer equation [47], I0/
I=1+Ksv[Q], where I0 and I represent the ﬂuorescence intensities in the
absence and thepresenceof thequencher [Q], respectively, andKsv is the
Stern–Volmer quenching constant, which is a measure of the accessi-
bility of Trp to acrylamide. Quenching studies with lipophylic probes
were performed by successive addition of small amounts of 5NS or 16NS
in ethanol to the samples of the peptide incubated with LUV. The ﬁnal
concentration of ethanol was kept below 2.5% (v/v) to avoid any
signiﬁcant bilayer alterations. After each addition an incubation period
of 15 minwas kept before the measurement. The data were analyzed as
previously described [44].
2.9. Fluorescence measurements using FPE-labeled membranes
LUVs with a mean diameter of 0.1 µm were prepared in buffer
containing 10 mM TRIS–HCl, pH 7.4. The vesicles were labeledexclusively in the outer bilayer leaﬂet with FPE as described previously
[48]. Brieﬂy, LUVs were incubated with 0.1 mol % FPE dissolved in
ethanol (nevermore than 0.1% of the total aqueous volume) at 37 °C for
1 h in the dark. Any remaining unincorporated FPEwas removed by gel
ﬁltration on a Sephadex G-25 column equilibrated with the appro-
priate buffer. FPE-vesicles were stored at 4 °C until use in an oxygen-
Table 2
Partition coefﬁcients, Stern–Volmer quenching constants and maximal leakage, hemifusion and fusion values for the E1PTM peptide incorporated in LUVs of different compositions
LUV compositions Kp Trp Kd (µM) FPE Ksv (M−1) Acrylamide Ksv (M−1) 5-NS Ksv (M−1) 16-NS Leakage (max%) Hemifusion (max%) Fusion (max%)
EPG/Chol 5:1 4.40±0.1 ·107 1.4±0.1 ·106 4.82 2.34 2.02 92 33 19
EPA/Chol 5:1 1.60±0.1 ·107 1.3±0.1 ·106 2.39 6.23 4.47 91 23 14
BPS/Chol 5:1 8.03±0.5 ·106 1.6±0.1 ·106 6.51 1.51 1.66 98 35 28
EPC/Chol 5:1 7.10±0.4 ·106 3.4±0.1 ·106 5.58 2.06 1.63 96 19 12
LIVER EXTRACT 3.02±0.4 ·106 6.2±0.2 ·106 8.43 7.85 3.76 45 15 9
EPC/TPE 4:1 – – – – – 61 50 39
EPC/LPC 4:1 – – – – – 100 98 45
E1PTM in buffer – – 17.87 – – – – –
Fig. 3. Stern–Volmer plots of the quenching of the Trp ﬂuorescence emission of E1PTM by
(A) acrylamide and (B) 5NS (ﬁlled symbols) and 16NS (empty symbols) in the presence
of LUVs. Quenching of the Trp ﬂuorescence emission by acrylamide in aqueous buffer
(V) and in the presence of LUVs composed of EPC/Chol at amolar ratio of 5:1 (○,●), BPS/
Chol at a molar ratio of 5:1 (w ,x), EPG/Chol at a molar ratio of 5:1 (☆,★), EPA/Chol at a
molar ratio of 5:1 (△,▲) and lipid liver extract (□,■). The lipid to peptide ratio was 50:1.
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weremeasured after the desired amount of peptide, dissolved in buffer
containing 5% triﬂuoroethanol, was added into 400 µl of lipid
suspensions (200 µM lipid) using a Varian Cary Eclipse ﬂuorescence
spectrometer. Excitation and emission wavelengths were set at 490
and 520 nm, respectively, using excitation and emission slits set at
5 nm. Temperature was controlled with a thermostatic bath at 25 °C.
The contribution of light scattering to the ﬂuorescence signals was
measured in experimentswithout the dye andwas subtracted from the
ﬂuorescence traces. Data were ﬁtted either to a hyperbolic binding
model [49] using the following equation, F=(Fmax[P]) / (Kd+[P]), where
F is the ﬂuorescence variation, Fmax the maximum ﬂuorescence
variation, [P] the peptide concentration, and Kd the dissociation
constant of the membrane binding process. The experimental points
shown in the ﬁgures are the mean values of at least three
measurements.
2.10. Measurement of the membrane dipole potential using
Di-8-ANEPPS-labeled membranes
Aliquots containing the appropriate amount of lipid in chloro-
form-methanol (2:1 vol/vol) and di-8-ANEPPS were placed in a test
tube to obtain a probe/lipid molar ratio of 1/100 and LUVs, with a
mean diameter of 90 nm, were prepared as described previously.
Steady-state ﬂuorescence measurements were recorded with a
Varian Cary Eclipse spectroﬂuorimeter. Dual wavelength recordings
with the dye di-8-ANEPPS were obtained by exciting the samples at
two different wavelengths (450 and 520 nm) and measuring their
intensity ratio, R450/520, at an emissionwavelength of 620 nm [50,51].
Changes in the total membrane dipole moment cause a shift in the
excitation spectrum maximum of di-8-ANEPPS. By exciting the
membrane suspensions at two different wavelengths corresponding
to the maximum and the minimum of the difference spectrum, a
ﬂuorescence intensity ratio R can be calculated, which can be used as
a measure of the relative changes in the magnitude of the dipole
potential. The ﬂuorescence ratio R is deﬁned as the ratio of the
ﬂuorescence intensity at an excitationwavelength of 450 nm divided
by that at 520 nm. The peptide, dissolved in buffer containing 5%
triﬂuoroethanol, was added to attain the suitable peptide/lipidmolar
ratio. The lipid concentration was 200 µM, and all experiments were
performed at 25 °C.
2.11. Infrared spectroscopy
For infrared spectroscopy, liposomes prepared as above but in
D2O buffer, were added to a vial containing lyophilized peptide and
resuspended with intermittent vortexing for 30 min. The samples
were frozen and thawed ﬁve times to ensure complete homogeniza-
tion and maximization of peptide/lipid contacts with occasional
vortexing. Approximately 25 µl of a pelleted sample were placed
between two CaF2 windows separated by 50-µm thick Teﬂon spacers
in a liquid demountable cell (Harrick, Ossining, NY). The spectrawere
obtained in a Bruker IFS55 spectrometer using a deuteratedtriglycine sulfate detector. Each spectrumwas obtained by collecting
200 interferogramswith a nominal resolution of 2 cm−1, transformed
using triangular apodization and, in order to average background
spectra between sample spectra over the same time period, a sample
shuttle accessory was used to obtain sample and background spectra.
The spectrometer was continuously purged with dry air at a dew
point of −40 °C in order to remove atmospheric water vapor from the
bands of interest. All samples were equilibrated at the lowest
temperature for 20 min before acquisition. An external bath
circulator, connected to the infrared spectrometer, controlled the
sample temperature. For temperature studies, samples were scanned
Fig. 4. Effect of the E1PTM peptide on (A)membrane rupture, (B) hemifusion, (C) fusion ofﬂuorescent probes encapsulated in LUVs containing different lipid compositions at different lipid-
to-peptidemolar ratios. The lipid compositions usedwere EPC/Chol at amolar ratio of 5:1 (○), BPS/Chol at amolar ratio of 5:1 (w), EPG/Chol at amolar ratio of 5:1 (☆), EPA/Chol at amolar
ratio of 5:1 (△), lipid liver extract (□), EPC/LPC at a molar ratio of 4:1 (✳) and EPC/TPE at a molar ratio of 4:1 ( ).The lines connecting the experimental data are merely guides to the eye.
Release of (D) FD10 and (E) FD20 after addition of the E1PTM peptide from LUVs composed of (1) EPC/LPC at a molar ratio of 4:1, (2) EPG/Chol at amolar ratio of 5:1, (3) EPA/Chol at amolar
ratio of 5:1, (4) BPS/Chol at a molar ratio of 5:1, (5) EPC/Chol at a molar ratio of 5:1, (6) lipid liver extract and (7) EPC/TPE at a molar ratio of 4:1. The lipid to peptide ratio was 15:1.
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scan. The data were analyzed as previously described [43,44].
2.12. Hydrophobic moment, hydrophobicity, and interfaciality
The hydrophobic moment calculations were carried out according
to Eisenberg et al. [52] and the scale for calculating hydrophobic
moments was taken from Engelman et al. [53]. Hydrophobicity and
interfacial values, i.e., whole residue scales for the transfer of an amino
acid of an unfolded chain into the membrane hydrocarbon palisade
and the membrane interface respectively, have been obtained from
http://blanco.biomol.uci.edu/hydrophobicity_scales.html [54]. Each
speciﬁc value in the two-dimensional plot represents the mean of
the values pertaining to the hydrophobic moment, hydrophobicity
and interfaciality of the amino acid at that position and its neighbours
[55]. Positive values correspond to positive bilayer-to-water transfer
free-energy values and therefore, the higher the value, the greater the
probability to interact with the membrane surface and/or the
hydrophobic core.
3. Results
The HCV E1 envelope glycoprotein is thought to be responsible for
the membrane fusion process whereas the HCV E2 envelope glycopro-
tein is thought to mediate the binding to the host cell, although other
roles could not be ruled out [17,19,25]. In Fig.1we present the analysis of
the hydrophobicmoment, hydrophobicity and interfaciality distribution
along the E1 envelope glycoprotein sequence of HCV_1B4J strain as-suming it forms an α-helical wheel along the whole sequence [29].
Although the E1 and E2 HCV envelope glycoproteins are supposed to be
class II membrane fusion proteins and therefore their α-helix content
should not be as high as that of class I membrane fusion proteins, these
data display the potential surface zones that could be implicated in
the modulation of membrane binding and/or protein interaction. As
we have shown previously, HCV E1 includes a highly membranotropic
region immediately adjacent to the E1 TM domain (Fig. 1). As shown in
Table 1, this region is signiﬁcantly conserved among the major
genotypes of HCV. Since this region, similarly to other pre-transmem-
brane regions of other fusion proteins, could be important in the
membrane fusion process [56], we present here the results of the study
of the interaction of a peptide derived from this region with model
membranes, the E1PTM peptide, comprising residues 309–340 (Fig. 1).
Peptide E1PTM has been patterned after peptides 18 (309-YPGHVSGHR-
MAWDMMMNW-326), 19 (316-HRMAWDMMMNWSPTTALV-333) and 20
(323-MMNWSPTTALVVSQLLRI-340) from the original HCV E1 peptide
library [29].
The interaction of the E1PTM peptide with membrane vesicles was
followed by the change of the ﬂuorescence emission of the two Trp
residues in the presence of model membranes containing different
phospholipid compositions at different lipid/peptide ratios [57]. Upon
the addition of liposomes, a concomitant blue shift and an increase of
the ﬂuorescence emission maximum were observed, indicating that
the Trp residues of the peptide were in a hydrophobic environment
(Fig. 2A). Kp values in the range 107–106were obtained for the different
phospholipid compositions studied (Table 2). These Kp values show
that the peptidewas bound to themembrane surfacewith high afﬁnity
Fig. 5. Steady-state anisotropy values,brN, as a function of temperature of (A, C, E, G) TMA-DPHand (B, D, F, H)DPH incorporated intoMLVs composedof (A andB)DMPC, (C andD)DMPA, (E
and F)DMPG, and (G andH)EPC/SM/Chol at a lipidmolar ratio of 5:1:1. Data correspond to vesicles in the absence (○) and in the presence of the E1PTM peptide. (●). (I) Intrinsic steady-state
anisotropy of the E1PTM peptide as a function of temperature in solution (●) and incorporated intoMLVs composed of (w) DMPC, (□) DMPA, (☆) DMPG and (△) DMPS. The peptide-to-lipid
molar ratio was 1:15.
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emission frequency maximum of the Trp residues in the presence of
LUVs. In solution the peptide had an emission maximum centered
at 345 nm, typical for Trp in a polar environment, whereas in the
presence of increasing concentrations of liposomes the emission
maximum of the Trp residues presented a shift of about 10–11 nm to
lower wavelengths depending on liposome composition (data not
shown), implying that the Trp residues sensed a low-polarity en-
vironment upon interaction with the membrane. We have also used
the electrostatic surface potential probe FPE [61] to conﬁrm the bind-
ing of the E1PTM peptide to model membranes composed of differentlipid compositions at different lipid/peptide ratios (Fig. 2B). As ob-
served in the ﬁgure, E1PTM had a higher afﬁnity for model membranes
containing negatively-charged phospholipids than for the other
compositions, including the liver lipid extract (Table 2). Changes in
the magnitude of the membrane dipole potential elicited by E1PTM
were monitored by means of the spectral shift of the ﬂuorescence
probe di-8-ANEPPS [50,62,63]. The variation of the ﬂuorescence
intensity ratio R450/520 normalized as a function of the peptide con-
centration for different membrane compositions is shown in Fig. 2C,
demonstrating that the peptide was capable of inserting into the lipid
bilayer and modifying the dipole potential. In the presence of the
2076 A.J. Pérez-Berná et al. / Biochimica et Biophysica Acta 1778 (2008) 2069–2080peptide, the greater decrease in the R450/520 value was measured in
bilayers with negatively-charged lipids. Taking together all these data,
the peptide interacted strongly with membranes containing nega-
tively-charged phospholipids but also with zwitterionic ones.
Stern–Volmer plots for the quenching of Trp by acrylamide,
recorded in the absence and presence of lipid vesicles, are shown in
Fig. 3A. Linear Stern–Volmer plots indicate that the Trp residues are
fairly accessible to acrylamide, and in all cases, the quenching of the
peptide Trp residue showed an acrylamide dependent concentration
behavior. In aqueous solution the Trp residues were highly exposed to
the solvent that led to a more efﬁcient quenching. However, in the
presence of the phospholipid membranes, the extent of quenching
was signiﬁcantly reduced, indicating a poor accessibility of the Trp
residues to the aqueous phase, consistent with the incorporation of
the E1PTM peptide into the lipid bilayer. This notion is substantiated by
the lower Ksv values obtained from the Stern–Volmer plots (Table 2).
As expected, Ksv values were lower in the presence of negatively-
charged phospholipids, consistent with a deeper location in negative
bilayers. The transverse location of the peptide in the lipid bilayer
was investigated by monitoring the relative quenching of the Trp
ﬂuorescence by the lipophylic spin probes 5NS and 16NS. The var-
iation of the ﬂuorescence intensity as a function of the effective con-
centration of both 5NS and 16NS probes is shown in Fig. 3B, whereas
the Ksv values for both probes are presented in Table 2. It is observed
that, in general, 16NS quenches the peptide ﬂuorescence less
efﬁciently than 5NS. Although it should be taken into account that
the E1PTM peptide has two Trp residues in the middle of the peptide
sequence separated by ﬁve amino acids, these data suggest that it is
localized in a shallow position in the membrane, but deeper in model
membranes composed of negatively-charged phospholipids.
To examine the effect of the E1PTM peptide in the destabilization
of membrane vesicles, we studied the extent of CF leakage, i.e., mem-
brane rupture, at different peptide-to-lipid molar ratios and different
phospholipid compositions (Fig. 4A). It is interesting to note that the
E1PTMpeptide induced100%of leakage, evenat peptide-to-lipid ratios as
low as 0.0025, for liposomes composed of EPC/LPC (Fig. 4A). Signiﬁcant
leakage values betweenwere observed for liposomes composed of EPC/
Chol, BPS/Chol, EPG/Chol and EPA/Chol (at the highest peptide-to-lipid
ratio studied, i.e., 1:10, leakage values were about 90–100%). Lower
leakage values of about 60% and 40% were obtained for liposomesFig. 6. Temperature dependency of the phospholipid CH2 (○,●) and CfO ester group (□,■) st
(□,○) and in the presence (■,●) of the E1PTM peptide at a lipid-to-peptide molar ratio of 15composed of EPC/TPE and the lipid liver extract, respectively (Fig. 4A).
Perturbation of membranes is not sufﬁcient to complete the process of
viral and cellular membrane fusion, since it is also necessary for the
merge of the monolayers and the stalk formation, according to the
stalk model for membrane fusion [11]. However, there is not a clear
quantitative criterion to characterize fusion peptides using membrane
destabilization. Therefore, we have also studied the effect of the peptide
on both hemifusion and fusion using liposomes of different composi-
tions. As it has been shown previously [64], the energetic barrier for
hemifusion and fusion is larger than for leakage (pore formation). At
the same time, leakage values, as measured here, are usually higher
than hemifusion and fusion ones. The induction of outer and inner-
monolayer lipidmixing (hemifusion and true fusion, respectively) by the
E1PTM peptidewas tested with several types of vesicles utilizing a probe
dilution assay [45,46]. As shown in Fig. 4B and C and Table 2, the higher
hemifusion and fusion values were found for liposomes containing EPC/
LPC (about 100% hemifusion and 45% fusion, respectively, at a peptide-
to-lipid ratio of 1:5), whereas liposomes composedof EPC/TPE displayed
also signiﬁcantvalues (about45%hemifusion and35% fusion). Lower but
signiﬁcant hemifusion and fusion values were observed for the other
liposome compositions tested, the higher hemifusion and fusion values
were found for liposomes containing negatively-charged phospholipids
(Fig. 4B and C).
Twomainmodels of induced pores by peptides have beendescribed:
the barrel-stave model and the toroidal model [65,66], which in prin-
ciple could be distinguished from each other by performing leakage
assays using liposomes with different membrane curvature propensity
[67,68]. As commented above, the maximum leakage induced by the
E1PTM peptide was different depending on the speciﬁc phospholipid
composition of the liposomes, i.e., leakage was greater for LPC-con-
taining liposomes than for TPE-containing ones. It is known that pep-
tides which form toroidal pores tend to impose a positive curvature
tensionon themembrane that apparently facilitates the formationof the
pores [69]. The presence of lipid or molecules that facilitate a positive
curvature on the membrane, such as LPC, could then aid the formation
of toroidal pores, whereas the presence of lipid or molecules in the
membrane that facilitate a negative curvature, such as TPE, could inhibit
the formation of toroidal pores. According to the observed results
(Fig. 3B), it could then be possible that the E1PTM peptide might form
toroidal pores in themembrane. In order to characterize the pore size ofretching frequency values of (A) DMPC, (B) DMPA, (C) DMPG and (D) LPC in the absence
:1.
Fig. 7. Amide I′ band of the E1PTM peptide in (A) solution, and in the presence of (B) 40% of TFE, (C) LPC, (D) DMPC, (E), DMPG, and (F) DMPA at a lipid-to-peptide molar ratio of 15:1.
Spectra are displayed at two temperatures, 2 °C (····) and 50 °C (\).
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of experiments using FITC-dextrans of different sizes entrapped in
liposomes with different compositions (FD-10 and FD-20, having Stoke
radii around 23 Å and 33Å, respectively [70]). As observed in Fig. 4D and
E, the E1PTM peptidewas able to induce the leakage of FD10 entrapped in
liposomes but not of FD20. Since E1PTM promoted the leakage of CF
(Fig. 4A) and FD10 (Fig. 4D) but not of FD20 (Fig. 4E), the pore sizewhich
would be formed by the peptide should be comprised between 23 Å and
30 Å. In accordance with the CF data shown above, EPC/LPC liposomes
displayed a high FD10 leakage, but a low one in liposomes composed of
EPC/TPE (about 98% and 15% leakage, respectively). Apart from that, the
ability of E1PTM to induce leakage of encapsulated FD10 was larger in
model membranes composed of negatively-charged phospholipids.
The effect of the E1PTM peptide on the structural and thermotropic
properties of phospholipidmembraneswas investigated bymeasuring
the steady-state ﬂuorescence anisotropy of theﬂuorescent probes DPH
and TMA-DPH incorporated into model membranes composed of
saturated synthetic phospholipids as a function of temperature (Fig. 5).
For DMPC bilayers, E1PTM decreased the cooperativity of the thermal
transition as well as induced a slight increase of the anisotropy of all
types of probes above the Tm of the phospholipid (Fig. 5A and B). In the
case of DMPA, E1PTM did not affect signiﬁcantly the cooperativity of the
main gel-to-liquid transition but elicited a shift to higher temperatures
of about 4 °C and 2 °C for DPH and TMA-DPH, respectively (Fig. 5C
and D). Similarly to what was observed for DMPC, a small increase
in anisotropy was observed above Tm of the phospholipid. For vesicles
composed of DMPG, the E1PTM peptide slightly decreased the co-
operativity of the thermal transition, as well as it increased the
anisotropy above the Tm of the phospholipid (Fig. 5E and F). A relatively
complex lipid mixture, EPC/SM/Chol at a molar ratio of 5:1:1, was also
studied and similarly to what was observed above, i.e., the peptide
decreased the cooperativity of the main transition and a slightly in-
creased of the anisotropy above but not below Tm (Fig. 5G and H).
These results suggest that the difference in the charge between the
phospholipid headgroups affect, but slightly, the peptide incorporation
into the lipid bilayer as well as that it should be located at the lipid–
water interface inﬂuencing the ﬂuidity of the phospholipids [58].
We have also studied the intrinsic anisotropy of the Trp residues of
the peptide in the presence of liposomes composed of pure synthetic
phospholipids (Fig. 5I). In the presence of the phospholipids, theanisotropy values were different depending on temperature: they
were higher below the Tm of each speciﬁc phospholipid, whereas they
were lower above it. More important, the change in anisotropy oc-
curred coincidentally when the main gel-to-liquid phase transition of
each speciﬁc phospholipid took place; these data implied,ﬁrst, that the
peptide was effectively incorporated into the membrane palisade and
second, the peptidewas capable of sensing the phase transition of each
one of the phospholipids.
Although it has been shown that the incorporation of transmem-
brane peptides in the phospholipid palisade of the membrane can
affect not only the phospholipid chain order but also inter-chain
coupling, a shift in the frequency of the CH2 symmetric stretching band
is a reliable index of the phase behavior of phospholipid dispersions
[71]. The temperature dependence of the CH2 symmetric frequency of
pure DMPC is shown in Fig. 6A, where a highly cooperative change at
approximately 23 °C was observed, corresponding to the gel-to-liquid
crystalline phase transition, Tm, of the phospholipid. In the presence of
E1PTM, the cooperativity of the gel-to-liquid crystalline phase transi-
tion of DMPC was reduced, and the frequency of the CH2 symmetric
frequency decreased above but not below the Tmwhen comparedwith
the pure phospholipid. The frequency at the maximum of the CfO
vibration band for DMPC in the presence of the peptide, similarly to
what was observed for the CH2 frequency, displayed a less cooperative
transition than the pure phospholipid, but it was shifted to higher
temperatures (Fig. 6A). In the case of DMPA a highly cooperative
change corresponding to the main transition Tm of the phospholipid
was observed at approximately 48 °C (Fig. 6B). The presence of the
E1PTM peptide induced a shift of the Tm to higher temperatures as well
as a slight decrease in the cooperativity of the transition. Signiﬁcantly,
the frequencyof the CH2 symmetric frequency decreased abovebut not
below the Tm when compared with the pure phospholipid, indicating
that the peptide induced an increase in the proportion of trans isomers
when compared with the pure phospholipid. The frequency at the
maximum of the CfO vibration band displayed a large cooperative
transition corresponding to the gel-to-liquid crystalline phase transi-
tion of the phospholipid, but the intensity of the hydratedCfOgroup in
the presence of the peptide was higher than in its absence at
temperatures below but not above the Tm (Fig. 6B). When the peptide
was incorporated in DMPG, a slight decrease in the cooperativity of the
transitionwas observed (Fig. 6C). The frequency of the CH2 symmetric
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phospholipid, indicating that the proportion of trans isomers was
higher ad above the Tm. The frequency at the maximum of the CfO
vibration band of DMPGwas not signiﬁcantly affected by the presence
of the peptide, as observed in Fig. 6C. We have also examined the
temperature dependence of the stretching vibration bands of LPC in
the presence of the peptides, as observed in Fig. 6D. Interestingly, the
phase transition observed at about 4 °C for the pure phospholipid was
shifted to about 20 °C without any effect on the frequency neither
below nor above the transition (it should be recalled that pure LPC has
a transition from an interdigitated phase to a micellar one). The same
effectwas observedwhen observing the CfO vibration band frequency
(Fig. 6C). These results conﬁrm that the E1PTM peptide is capable of
inserting into the palisade structure of the membrane affecting the
phospholipid acyl chains packing, as well as altering the order degree
of the bilayer.
The existence of structural changes on the E1PTM peptide induced by
membrane bindingwas studied by analyzing the infrared Amide I′ band
located between 1700 and 1600 cm−1 in membranes by infrared
spectroscopy (Fig. 7). TheAmide I′ region of the fully hydrated peptide in
buffer is shown in Fig. 7A. Two main bands are apparent, a broad one
with a maximum at about 1648 cm−1 and a narrow band with a maxi-
mum at about 1616 cm−1. The band with the intensity maxima at
about 1648 cm−1 would correspond to a mixture of unordered but also
helical structures, whereas the bandwith the intensitymaxima at about
1616 cm−1 would corresponds to aggregated structures [72,73]. The
maximumof the bands did not change signiﬁcantly upon increasing the
temperature, suggesting a high degree of conformational stability of the
peptide. The Amide I′ band of the peptide in the presence of TFE and LPC
displayed a maximum at about 1648 cm−1 and 1649 cm−1, respectively,
indicating that the structure of the peptide corresponds to a mixture of
unordered and helical structures (Fig. 7B and C). The band envelope of
the Amide I′ region of the peptide bound to DMPC model membranes
at a phospholipid/peptide molar ratio of 15:1 was different from that
seen for the pure peptide in solution but similar to the Amide I′ band
observed in thepresence of TFE and LPC, displaying amaximumat about
1648 cm−1 (Fig. 7D). However, the band envelope of the Amide I′ region
of the peptide bound to DMPG and DMPAmembranes was signiﬁcantly
different from that seen for the pure peptide in solution (Fig. 7E and F),
since the intensitymaximawere 1615 cm−1 and 1617 cm−1, respectively.
In this case, the structure of the peptide corresponds mainly to ag-
gregated structures. As it was found for the peptide in solution, the
maximum of the band did not change signiﬁcantly upon increasing the
temperature in the presence of the membranes, indicating also a high
degree of conformational stability.
4. Discussion
It is known that the region immediately adjacent to the membrane-
spanning domain of differentmembrane fusion proteins plays an essen-
tial role in the fusogenic activities of these proteins [31–33,74–76]. The
segment encompassing residues 309–340 of HCV E1 glycoprotein
is located immediately adjacent to the TM domain, is capable of de-
stabilizing model membranes, presents a localized high hydrophobic
moment surface area, could be involved in membrane destabilization
similarly to the PTM domain of class I fusion proteins and is highly
conserved in all strains of HCV [34–36]. Interestingly, part of the E1PTM
sequence is a conserved hydrophobic-heptad repeat and site-directed
mutagenesis of this sequence affects signiﬁcantly viral entry [77]. Con-
sequently, we havemade a comprehensive study of a peptide patterned
after the E1 region, E1PTM, characterizing its binding and interaction
with model membrane systems.
Peptide E1PTM has a signiﬁcant membranotropic activity and
displays a high binding constant in the presence of model membranes
having different phospholipid compositions, similarly to what has
been found for other peptides [43,44]. After binding, the Trp residues ofthe peptide reside in an environment with a low dielectric constant
showing a signiﬁcant motional restriction. E1PTM showed a slightly
higher afﬁnity for anionic-phospholipid compositions, possibly due
to the fact that the peptide has a positive net charge at pH 7.4. The
existence of a speciﬁc interaction with liposomes containing nega-
tively-charged phospholipids was corroborated by the change of the
dipole potential at themembrane surface, aswell as byhydrophilic and
lipophylic probe quenching, suggesting that the E1PTM peptide was
effectively incorporated into themembranes, but located nearer to the
membrane surface in the presence of zwitterionic phospholipids than
in the presence of negatively-charged ones.
The E1PTM peptide was also capable of disrupting the membrane
bilayer causing the release of ﬂuorescent probes, this effect being de-
pendent on lipid composition and on the lipid/peptide molar ratio. The
highest effectwasobserved for liposomes containingnegatively-charged
phospholipids, but signiﬁcant leakage values were also observed for
liposomes composed of zwitterionic phospholipids. The induction of
hemifusion and fusion by E1PTM were also studied and similar results
were obtained, since speciﬁc and largemembranehemifusion and fusion
values were found in the presence of liposomes composed of both
negatively-charged phospholipids and zwitterionic ones. Interestingly,
liposomes containing TPE (phospholipid inducing negative curvature)
displayed relatively low hemifusion and fusion values, whereas, on the
contrary, liposomes containing LPC (phospholipid inducing positive
curvature) were the ones that elicited the most. These data reveal that
E1PTM affects theﬂuidity behavior of thephospholipids in themembrane
suggesting that the E1PTM peptide, although interacting with the mem-
brane, should be located at the lipid–water interface [58]. Notably, E1PTM
released CF and FD10 but not FD20, implying that the peptide formed
poreswithdiameter between23Åand30Å. The inductionof hemifusion
and fusion by the E1PTM peptide were also studied and similar results
were obtained, since speciﬁc and largemembranehemifusion and fusion
valueswere characteristic of liposomes composed of negatively-charged
phospholipids.
We have also shown that E1PTM peptide is capable of affecting the
steady-state ﬂuorescence anisotropy of ﬂuorescent probes located in
themembrane, since the peptide, in general, was able of decreasing the
mobility of the phospholipid acyl chains above but not below Tmwhen
compared to the pure phospholipids. Signiﬁcantly, the peptide sensed
the phospholipid main phase transition indicating its incorporation
into the membrane bilayer. The infrared spectra of the Amide I′ region
of the fully hydrated peptide did not changed with temperature,
indicating a high stability of its conformation, where a mixture of α-
helix, random and aggregated structures coexisted. However we have
observed differences on the proportion of the different secondary
elements when the peptide was incorporated into membranes of
different phospholipid compositions. Whereas the α-helix and
random content was similar in the presence of TFE, LPC or DMPC,
they changed signiﬁcantly in the presence of DMPG and DMPA, where
aggregated structures predominated. These data would suggest that
the presence of different phospholipid headgroups would modulate
the secondary structure of the peptide as it has been suggested for
other peptides [57,58,60].
The binding to the surface and the modulation of the phospholipid
biophysical properties which take place when E1PTM is bound to the
membrane, i.e., partitioning into the membrane surface and perturba-
tion of the bilayer architecture, could be related to the conformational
changes which might occur during the activity of the HCV E1 gly-
coprotein. These featureswould indicate that E1PTMwould interactwith
the membrane through both electrostatic and hydrophobic effects, as
well as it would be adsorbed at themembrane interface. The capacity of
E1PTM to induce an enhanced release of CF from liposomes containing
positive curvature-inducing phospholipids, such as LPC, could indicate
that this peptide would form pores, possibly through the formation of
toroidal-like structures [78]. Thesedata suggest that theE1 regionwhere
the E1PTM peptide resides might be a fusion determinant and have
2079A.J. Pérez-Berná et al. / Biochimica et Biophysica Acta 1778 (2008) 2069–2080an essential role in the membrane fusion process, overall in the de-
stabilization of the viral envelope membrane. If that were true, it would
imply that both HCV E1 and E2 glycoproteins are directly implicated in
the mechanism that makes possible the entry of the HCV virus into its
cellular host. Because this HCV E1 segment presents many similarities
with other domains from class I membrane fusion proteins, it is a
potential target for the developmentof inhibitormolecules of HCV entry
and/or membrane fusion.
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